Headquarters:
Copenhagen
Description:
Biotechnology company
Categories:
Biotechnology
Website:
http://www.zealandpharma.com

Detailed Description

Update

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of diabetes/metabolic diseases, and its lead drug invention is lixisenatide (Lyxumia® 1), a once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide is currently under regulatory review in a large number of countries globally, and in November 2012 the European Committee for Human Medicinal Products issued a positive recommendation for approval of the product in Europe.

Current Team (1)

Update

Board Members and Advisors (2)

Update

Offices/Locations (1)

Update
  • Office

    Smedeland 36

    Copenhagen, 2600

    DNK

Images (1)

Update
  • 92a3451e55c5909cf98f8001d1e7e6ee